'All action no talk': The role of HER2/neu in adjuvant therapy choice for gastric cancer

Annals of Oncology

Volumn 24, Issue 7, 2013, Pages 1715-1717

  Santini, D ^a   Vincenzi, B ^a   Pantano, F ^a,c   Schiavon, G ^b   Tonini, G ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c University of Lyon Claude Bernard   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; LAPATINIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; EDITORIAL; ESOPHAGUS CANCER; EXTERNAL BEAM RADIOTHERAPY; GASTRECTOMY; GASTROESOPHAGEAL JUNCTION CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; AKT SIGNALING; CANCER CHEMOTHERAPY; CHEMORADIOTHERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRIC CANCER SCORING SYSTEM; GASTROESOPHAGEAL JUNCTION; NEOADJUVANT THERAPY; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM;

EID: 84883825354     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt172     Document Type: Editorial

References (22)

1. Ross JS, Slodkowska EA, Symmans WF et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-368.
2. Yonemura Y, Ninomiya I, Yamaguchi A et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 51: 1034-1038.
3. Jorgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature. J Cancer 2012; 3: 137-144.
4. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697.
5. Im SA, Kim JW, Kim JS et al. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. Diagn Mol Pathol 2011; 20: 94-100.
6. Kunz PL, Mojtahed A, Fisher GA et al. HER2 expression in gastric and gastroesophageal Junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012; 20(1): 13-24.
7. Yan SY, Hu Y, Fan JG et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol 2011; 17: 1501-1506.
8. Yan B, Yau EX, Bte Omar SS et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010; 63: 839-842.
9. Kim KC, Koh YW, Chang HM et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011; 18(10): 2833-2840.
10. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529.
11. De Vita F, Giuliani F, Silvestris N et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 2010; 36 (Suppl. 3): S11-S15.
12. Gordon MA, Gundacker H, Benedetti J et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 2013; 24: 1754-1761.
13. Macdonald JS, Benedetti J, Smalley SR et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 2009; 27 (suppl): 205s, abstr. 4515.
14. Pegram M, Finn R, Arzoo K et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15: 537-547.
15. Hayes DF, Thor AD, Dressler LG et al. HER2 and response to paclitaxel in nodepositive breast cancer. N Engl J Med 2007; 357: 1496-1506.
16. Press MF, Sauter G, Buyse M et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011; 29: 859-867.
17. Knuefermann C, Lu Y, Liu B et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003; 22: 3205-3212.
18. Gong SJ, Jin CJ, Rha SY et al. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 2004; 214: 215-24.
19. Press MF, Slamon DJ, Flom KJ et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20: 3095-3105.
20. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52(7): 797-805.
21. Park YS, Hwang HS, Park HJ et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 2012; 43(3): 413-422.
22. Gown AM, Goldstein LC, Barry TS et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol 2008; 21(10): 1271-1277.